�New data, generated by Thomas Jung and colleagues, at Novartis Exploratory Development, Switzerland, experience indicated that a drug known presently as AEB071 can thin the clinical symptoms of psoriasis, a chronic, presently incurable autoimmune skin disease.
In the study, healthy volunteers and patients with psoriasis were administered AEB071 by mouth. Different groups of individuals received different doses of the dose, but all doses were well tolerated with no obvious face effects. The decrease in the clinical symptoms of psoriasis was associated with a reduced ability of immune cells known as lymphocytes to divide and express a soluble factor known as IL-2. The authors consequently suggest that AEB071 power be an effective new treatment for psoriasis, although they cautiousness that farther clinical trials are needful to more clearly set up that the drug is safe and effective.
"The PKC inhibitor AEB071 crataegus oxycantha be a therapeutic pick for psoriasis"
Click here to horizon article
Journal of Clinical Investigation (JCI)
The JCI is the publication of the American Society for Clinical Investigation, an honor society of physician-scientists.
Journal of Clinical Investigation
More info
